Results 261 to 270 of about 80,532 (301)

CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells. [PDF]

Cell Rep Med
Wang L, Wang Y, He X, Mo Z, Zhao M, Liang X, Hu K, Wang K, Yue Y, Mo G, Zhou Y, Hong R, Zhou L, Feng Y, Chen N, Shen L, Song X, Zeng W, Jia X, Shao Y, Zhang P, Xu M, Wang D, Hu Y, Yang L, Huang H.   +25 more
europepmc   +1 more source

Correction: CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models. [PDF]

BMC Cancer
Zhi L, Zhang Z, Gao Q, Shang C, He W, Wang Y, Guo C, Niu Z, Zhu W.   +8 more
europepmc   +1 more source

Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies. [PDF]

J Hematol Oncol
Lin Y, Xiao Z, Hu F, Zheng X, Zhang C, Wang Y, Liu Y, Huang D, Wang Z, Xia C, Weng Q, Zhang L, Zhao Y, Qi H, Shen Y, Chen Y, Zhang F, Wu J, Liu P, Xu J, Liu L, Zhu Y, Zhang J, Qian W, Liang A, Zhu X, Wang T, Zhang M, Wang J.   +28 more
europepmc   +1 more source

Nanobody-based CAR NK cells for possible immunotherapy of MICA⁺ tumors. [PDF]

PNAS Nexus
Verhaar ER, van Keizerswaard WJC, Knoflook A, Balligand T, Ploegh HL.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

CAR-NK cells: a promising cellular immunotherapy in lymphoma

Expert Opinion on Biological Therapy, 2022
New methods in cancer immunotherapy, such as chimeric antigen receptor (CAR)-T cells, have shown promising results in destroying malignant cells. However, limitations and side effects of CAR-T cell therapy, such as graft-versus-host disease (GVHD), neurotoxicity, and cytokine release syndrome, have motivated researchers to investigate safer alternative
Shaghayegh, Khanmohammadi, Nima, Rezaei
openaire   +2 more sources

Nonviral technologies can pave the way for CAR-NK cell therapy

Journal of Leukocyte Biology, 2023
Abstract Natural killer cells are a promising platform for cancer immunotherapy. Natural killer cells have high intrinsic killing capability, and the insertion of a chimeric antigen receptor can further enhance their antitumor potential. In first-in-human trials, chimeric antigen receptor–natural killer cells demonstrated strong clinical
Tobias Bexte, Lisa Marie Reindl, Evelyn Ullrich   +2 more
openaire   +2 more sources

Avoiding CAR-NK cell fratricide

Nature Cancer, 2022
openaire   +2 more sources